BridgeMD
New treatment option for Laryngeal Neoplasm
Official title Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer
ClinicalTrials.gov ID: NCT07391345
What this study is testing
- What it's testing
- This randomized phase III trial will compare the outcomes of three treatment modalities for early-stage glottic laryngeal cancer (T1-T2N0): transoral CO₂ laser microsurgery (TLM), volumetric modulated arc therapy (VMAT), and MRI-guided stereotactic ablative radiotherapy (MRI-SABR). The primary endpoint is local control (LC).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years.
- Histologically confirmed squamous cell carcinoma of the glottic larynx, including verrucous carcinoma.
- Stage T1-T2N0 (8th TNM edition).
- ECOG performance status 0-2.
- Able to understand Lithuanian and complete questionnaires.
You likely can't join if
- AJCC stage III-IV laryngeal cancer.
- Prior radiotherapy for head and neck cancer.
- Pregnancy or breastfeeding.
- Contraindications for radiotherapy or inability to follow-up.
- Presence of another active malignancy.
- Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, clinically significant arrhythmia) or any condition that...
See the full eligibility criteria
- Age ≥18 years.
- Histologically confirmed squamous cell carcinoma of the glottic larynx, including verrucous carcinoma.
- Stage T1-T2N0 (8th TNM edition).
- ECOG performance status 0-2.
- Able to understand Lithuanian and complete questionnaires.
- Signed informed consent.
- AJCC stage III-IV laryngeal cancer.
- Prior radiotherapy for head and neck cancer.
- Pregnancy or breastfeeding.
- Contraindications for radiotherapy or inability to follow-up.
- Presence of another active malignancy.
- Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, clinically significant arrhythmia) or any condition that would preclude radiotherapy or adequate follow-up per investigator...
The study team makes the final eligibility decision.
Where it's taking place
- Kaunas, Lithuania
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kaunas, Lithuania. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.